Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
The Lancet. Oncology
|
January 2, 2013
Aristolochia: the malignant truth
Daniel Krell, Justin Stebbing
Future Science OA
|
March 8, 2016
<i>HOT</i> mutation screening in human glioblastomas
Daniel Krell, Paul Mulholland, Justin Stebbing, et al.
Plos One
|
June 1, 2011
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma
Daniel Krell, Mawuelikem Assoku, Malcolm Galloway, et al.
Future Oncology (London, England)
|
December 4, 2013
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets
Daniel Krell, Paul Mulholland, Adam E Frampton, et al.
Journal of Gastrointestinal Cancer
|
June 23, 2025
Mixed Neuroendocrine and Non-neuroendocrine Tumor of Pancreato-Biliary Origin Treated Successfully with Peptide Receptor Radionuclide Therapy
Kalyan Mansukhbhai Shekhda, Tu Vinh Luong, Daniel Krell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 24, 2017
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
Daniel Krell, Fran Said Battistino, Sarah Benafif, et al.
Expert Review of Anticancer Therapy
|
November 27, 2012
Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways
Adam E Frampton, Jonathan Krell, Elisa Giovannetti, et al.
Journal of Neuroendocrinology
|
September 19, 2022
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): Prevalence, clinicopathological characteristics and survival outcome in a cohort of 311 patients with well-differentiated lung neuroendocrine tumours
Aimee R Hayes, Tu Vinh Luong, Jamie Banks, et al.
Pancreas
|
May 3, 2021
High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis
Aimee R Hayes, Myles Furnace, Ruchir Shah, et al.
Plos One
|
May 28, 2016
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Nicholas Brown, Catherine McBain, Stephen Nash, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
The Lancet. Oncology
|
January 2, 2013
Aristolochia: the malignant truth
Daniel Krell, Justin Stebbing
Future Science OA
|
March 8, 2016
<i>HOT</i> mutation screening in human glioblastomas
Daniel Krell, Paul Mulholland, Justin Stebbing, et al.
Plos One
|
June 1, 2011
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma
Daniel Krell, Mawuelikem Assoku, Malcolm Galloway, et al.
Future Oncology (London, England)
|
December 4, 2013
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets
Daniel Krell, Paul Mulholland, Adam E Frampton, et al.
Journal of Gastrointestinal Cancer
|
June 23, 2025
Mixed Neuroendocrine and Non-neuroendocrine Tumor of Pancreato-Biliary Origin Treated Successfully with Peptide Receptor Radionuclide Therapy
Kalyan Mansukhbhai Shekhda, Tu Vinh Luong, Daniel Krell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 24, 2017
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
Daniel Krell, Fran Said Battistino, Sarah Benafif, et al.
Expert Review of Anticancer Therapy
|
November 27, 2012
Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways
Adam E Frampton, Jonathan Krell, Elisa Giovannetti, et al.
Journal of Neuroendocrinology
|
September 19, 2022
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): Prevalence, clinicopathological characteristics and survival outcome in a cohort of 311 patients with well-differentiated lung neuroendocrine tumours
Aimee R Hayes, Tu Vinh Luong, Jamie Banks, et al.
Pancreas
|
May 3, 2021
High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis
Aimee R Hayes, Myles Furnace, Ruchir Shah, et al.
Plos One
|
May 28, 2016
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Nicholas Brown, Catherine McBain, Stephen Nash, et al.
Page
of 2